

## **BPI and IncellDx, Inc. Announce OEM and International Distribution Agreement for Single Cell Immuno-Oncology and Oncology Diagnostic Products in Middle East and North Africa (MENA)**

MENLO PARK, CA; BPI announced today that it has signed an exclusive OEM and International Distribution agreement for IncellDx, Inc. single cell immune-oncology and oncology diagnostic products in the Middle East, North Africa (MENA). Products include IncellDx's proprietary single cell quantification of Programmed Death Ligand 1 (PD-L1) on tumor cells and immune cell subtypes in Lung, Bladder, and Head & Neck cancer; single cell HPV E6/E7 mRNA detection for cervical cancer; and IncellPREP™ tissue single cell suspension system for solid tumors. BPI will be the first company to offer the quantitative PD-L1 assay with cell cycle using flow cytometric or circulating tumor cell (CTC) technology in the region.

Bernard Tannoury, Chairman and CEO of BPI stated: "In collaboration with IncellDx, BPI will be able to provide the patient and healthcare community in the MENA region with revolutionary single cell quantitative, qualitative and fast diagnostics technology. We are thrilled to collaborate with IncellDx, an innovative and dynamic company and pair it with BPI's extensive expertise in the healthcare field in the region; our partnership reaffirms BPI's long standing commitment to improve the patient's quality of life and delivers on BPI's strategy to developing strong collaborations and vibrant partnerships."

Dr. Bruce Patterson, CEO of IncellDx said: "We look forward to this exciting business venture with BPI, a leader in pharmaceuticals and biotechnology in the region. For the first time, our 3Dx technology used in all of our immune-oncology and oncology products which powerfully combines multiplex RNA *in situ* hybridization/quantification, multiplex protein quantification, and DNA cell cycle simultaneously in individual cells will be sold in this growth market. Our assay platform yields unparalleled amounts of information on every cell in a heterogeneous tumor environment to better serve the needs of the healthcare market and practitioners. This assay platform can be used on flow cytometers, fluorescence microscopes, and CTC machines which are commonly used in diagnostic laboratories."

### **About Benta, Inc.**

BPI, a leader in the healthcare and pharmaceutical industry is committed to improving human health and wellbeing through the manufacturing pharmaceutical products, medical devices as healthcare products including diagnostic and prognostic technology.

BPI has become a front runner in manufacturing enhanced formulations for the treatment of a wide range of diseases. It also produces oncology, biotech and sterile products.

BPI has earned a number of International, regional, and local certificates including the European Good Manufacturing Practice (GMP) and ISO 9001: 2008.

### **About IncellDx, Inc.**

IncellDx, Inc., located at Menlo Park, California is a single cell diagnostic company committed to advancing Precision Medicine by offering transformative diagnostic and

prognostic clinical patient information based on an innovative technology platform that enables quantitative, simultaneous cell classification and single cell protein analysis, multiplex RNA *in situ* hybridization, and DNA cell cycle analysis. The Company develops products designed to address pressing unmet clinical needs in the advancement of cancer care.